SANOFI INDIA LIMITED
Latest filings
Next results: Thu, 29 Oct · Financial Results/Dividend- Board meeting on 29 Oct 2026 to consider Q2 FY26 results and interim dividend · Results
- Routine quarterly compliance certificate from registrar for Q2 FY27 · Compliance
- Promoter group inter-se transfer of 15.20 percent stake in Sanofi India · Strategic Transactions
Snapshot
What the business is, and whether it's a good one at a fair price.
Markets and sells insulin and other diabetes therapies in India, anchored on Lantus, Toujeo and the fixed-dose combination Soliqua. Alongside the diabetes franchise, the company distributes a legacy portfolio of cardiovascular, CNS and oral anti-diabetic brands through partnership agreements, with management describing this as the second pillar of a transformed business model. Public-sector expansion into CGHS, ESI, railways, defence and state rate contracts is a stated growth lever, alongside Tier 2/3 city penetration. Exports are a residual line — they collapsed after the 2020 divestment of the Ankleshwar manufacturing site to Zentiva, with Russia and South Africa now partially offsetting the gap; management says exports are only ~8% of PBT. No new product launches are planned for 2026; the development pipeline referenced is Teizeild, Brivekimig and Frexalimab. Costs are dominated by personnel and operating expenses, with FY26 opex down 17% on a partnership-driven restructuring tied to the Emcure deal.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY24 — not investment advice
Not enough history to assess.Charts
How has the market priced it — with filings on the timeline?
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from SANOFI INDIA LIMITED's filed financials and exchange disclosures
What does SANOFI INDIA LIMITED do?
SANOFI INDIA LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SANOFI.
Is SANOFI INDIA LIMITED profitable?
Yes. Over the trailing twelve months SANOFI INDIA LIMITED reported a net profit of ₹413 Cr on revenue of ₹2,235 Cr.
Is SANOFI INDIA LIMITED debt-free?
Yes. It reported no borrowings on its 31 Dec 2024 balance sheet, and ₹284 Cr of cash.
Is SANOFI INDIA LIMITED expensive compared with its peers?
On trailing P/E, SANOFI INDIA LIMITED ranks 41 of 158 in Pharmaceuticals — cheaper than 75% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.
How much does the SANOFI INDIA LIMITED share price move in a day?
On a typical session SANOFI INDIA LIMITED moves 0.74% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
When are SANOFI INDIA LIMITED's next results?
Financial Results/Dividend on Thu, 29 Oct. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track SANOFI INDIA LIMITED's announcements?
Every NSE and BSE filing by SANOFI INDIA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.